Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Angew Chem Int Ed Engl ; 63(4): e202316662, 2024 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-38059768

RESUMO

Aryl-maleimides undergo a novel [2+4]-photodimerization instead of the expected [2+2]-photodimerization under both direct irradiation with visible light and under sensitized energy transfer conditions. This new excited state reactivity in aryl-maleimides is deciphered through photochemical, photophysical, and spectroscopic studies. The stereochemistry of the photodimer depends on the type of non-bonding interactions prevalent during photodimerization which is in turn dictated by the substituents on the maleimide ring. More importantly, the stereochemistry of the photodimer formed is complementary to the product observed under thermal conditions.

2.
Neurophotonics ; 9(Suppl 1): 013001, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-35493335

RESUMO

Neurophotonics was launched in 2014 coinciding with the launch of the BRAIN Initiative focused on development of technologies for advancement of neuroscience. For the last seven years, Neurophotonics' agenda has been well aligned with this focus on neurotechnologies featuring new optical methods and tools applicable to brain studies. While the BRAIN Initiative 2.0 is pivoting towards applications of these novel tools in the quest to understand the brain, this status report reviews an extensive and diverse toolkit of novel methods to explore brain function that have emerged from the BRAIN Initiative and related large-scale efforts for measurement and manipulation of brain structure and function. Here, we focus on neurophotonic tools mostly applicable to animal studies. A companion report, scheduled to appear later this year, will cover diffuse optical imaging methods applicable to noninvasive human studies. For each domain, we outline the current state-of-the-art of the respective technologies, identify the areas where innovation is needed, and provide an outlook for the future directions.

3.
Chem Soc Rev ; 50(3): 1617-1641, 2021 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-33416818

RESUMO

This review highlights the excited state characteristics of imines and processes that govern their photochemical and photophysical properties. This review examines the pathways for deactivation and types of photochemical reactions that originate from excited imines. This review also features recent strategies that are developed to circumvent the fundamental issues that have plagued the development of the aza Paternò-Büchi reaction.

5.
J Am Chem Soc ; 140(41): 13185-13189, 2018 10 17.
Artigo em Inglês | MEDLINE | ID: mdl-30256105

RESUMO

The textbook photoreaction between two alkenes is the [2 + 2]-photocycloaddition resulting in functionalized cyclobutanes. Herein, we disclose an unusual reactivity of alkenes that favor photoene reaction over the [2 + 2]-photocycloaddition.

6.
Chem Commun (Camb) ; 54(78): 11021-11024, 2018 Sep 27.
Artigo em Inglês | MEDLINE | ID: mdl-30215437

RESUMO

Conjugate addition occurs efficiently from excited hydrazide based acrylanilides under both UV and metal free visible light irradiations. The reaction proceeds via an excited state encounter complex that bifurcates either via an electron or energy transfer pathway. The generality of excited state conjugate addition is demonstrated using chloromethylation and by thiol addition.

7.
Am J Reprod Immunol ; 66(5): 394-403, 2011 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-21623994

RESUMO

PROBLEM: We sought to answer two questions: First, is there a group of patients who benefit from intravenous immunoglobulin (IVIG) in IVF? Second can this group of patients be identified by preconception blood testing? METHOD OF STUDY: A total of 202 IVF cycles in subfertile women were divided into four groups. Group I: 62 cycles with preconception Th1:Th2 ratio and/or % CD56(+) cell elevation using IVIG; Group II: 27 cycles with similar Th1:Th2 and/or % CD56(+) cell elevation not using IVIG; Group III: 71 cycles with normal Th1:Th2 and/or % CD56(+) cell levels using IVIG; Group IV: 42 cycles with normal Th1:Th2 and % CD56(+) levels not using IVIG. These groups were similar with regard to patient age, diagnosis, and past failure history. RESULTS: The implantation rate (number of gestational sacs per embryo transferred, with an average of two embryos transferred per cycle) was 45% (55/123), 22% (12/54), 54% (75/139), and 48% (40/84) for Groups I-IV, respectively. The clinical pregnancy rate (fetal heart activity per IVF cycle started) was 61% (38/62), 26% (7/27), 69% (49/71), and 71% (30/42), respectively. The live birth rate was 58% (36/62), 22% (6/27), 61% (43/71), and 71% (30/42), respectively, and the live birth per embryo transferred was 40% (49/123), 13% (7/24), 43% (60/139), and 48% (40/84), respectively. There was a significant improvement in implantation, clinical pregnancy, live birth rate and live birth rate per embryo transferred for Group I versus Group II (P = 0.0032, 0.0021, 0.0017, and 0.0002, respectively) and for Group II versus Group IV (P = 0.0021, 0.0002, <0.0001 and <0.0001, respectively). There was no significant difference in success rates between Groups I and III (P = 0.085, 0.23, 0.45, 0.34, respectively) and between Groups III and IV (P = 0.22, 0.48, 0.17, 0.31, respectively). CONCLUSION: In subfertile women with preconception Th1:Th2 and/or % CD56(+) cell elevation, IVF success rates are low without IVIG therapy but significantly improve with IVIG therapy. In patients with normal Th1:Th2 and normal CD56(+) cell levels, IVF success rates were not further improved with IVIG therapy. IVIG may be a useful treatment option for patients with previous IVF failure and preconception Th1:Th2 and/or NK elevation. Preconception immune testing may be a critical tool for determining which patients will benefit from IVIG therapy. Prospective controlled studies (preferably double-blind, stratified, and randomized) are needed for confirmation.


Assuntos
Antígeno CD56/metabolismo , Citocinas/metabolismo , Fertilização in vitro/métodos , Imunoglobulinas Intravenosas/uso terapêutico , Infertilidade/terapia , Células Th1/imunologia , Células Th2/imunologia , Adulto , Implantação do Embrião , Transferência Embrionária , Feminino , Humanos , Imunoglobulinas Intravenosas/imunologia , Infertilidade/imunologia , Nascido Vivo , Cuidado Pré-Concepcional , Valor Preditivo dos Testes , Gravidez , Taxa de Gravidez , Resultado do Tratamento
8.
Am J Reprod Immunol ; 66(3): 237-41, 2011 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-21501282

RESUMO

PROBLEM: This study compares the birth defect rate in women using preconception TNF-α inhibitor (Adalimumab) during an in vitro fertilization (IVF) cycle to a similar population of women not using these immunologic therapies. METHOD OF STUDY: One hundred subfertile women aged ≤38years experienced ongoing pregnancies of which 36 resulted in twin pregnancies (136 babies). These successful cycles were divided into two different treatment groups: group I comprised 31 cycles (23 ICSI) using preconception Adalimumab (Humira) with or without pre- or post-conception intravenous immunoglobulin (IVIG) (last dose of Humira given 65.3±41.5days before embryo transfer). Group II comprised 69 cycles (58 ICSI) with no exposure to Humira or IVIG. Group I included all eligible fresh cycles containing at least five 5-celled embryos on day 3. Group II had similar entry criteria, but eligible cycles were randomly selected owing to a larger population size. Patients were later contacted by the clinic for neonatal health information. RESULTS: Delivery outcomes were as follows: group I experienced one case of DiGeorge syndrome (chromosome 22 deletion) that was electively terminated out of 41 babies (10 sets of twins) delivered. Group II experienced one case of neonatal heart defect and another case of Edward's syndrome (Trisomy 18) out of 95 babies (26 sets of twins) delivered. The anomaly rate was 2.44% (1/41) and 2.11% (2/95) for groups I and II, respectively, comparable to the expected birth defect rate for the normal IVF population. CONCLUSION: Preconception TNF-α inhibitor does not appear to increase the birth defect rate in women undergoing IVF. A larger, clinical trial with blinded delivery assessment is needed to confirm these safety conclusions.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Anormalidades Congênitas/epidemiologia , Adalimumab , Adulto , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/uso terapêutico , Enoxaparina/administração & dosagem , Feminino , Fertilização in vitro , Humanos , Infertilidade Feminina , Interleucina-10/sangue , Gravidez , Equilíbrio Th1-Th2 , Fator de Necrose Tumoral alfa/sangue
9.
Am J Reprod Immunol ; 61(2): 113-20, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19055656

RESUMO

PROBLEM: The purpose of this study was to investigate whether treatment with TNF-alpha inhibitors and/or intravenous immunoglobulin (IVIG) increases in vitro fertilization (IVF) success rates among young (<38 years) women with infertility and T helper 1/T helper 2 cytokine elevation. METHOD OF STUDY: Seventy-five sub-fertile women with Th1/Th2 cytokine elevation were divided into four groups: Group I: Forty-one patients using both IVIG and Adalimumab (Humira), Group II: Twenty-three patients using IVIG, Group III: Six patients using Humira, and Group IV: Five patients using no IVIG or Humira. RESULTS: The implantation rate (number of gestational sacs per embryo transferred, with an average of two embryos transferred by cycle) was 59% (50/85), 47% (21/45), 31% (4/13) and 0% (0/9) for groups I, II, III and IV respectively. The clinical pregnancy rate (fetal heart activity per IVF cycle started) was 80% (33/41), 57% (13/23), 50% (3/6) and 0% (0/5) and the live birth rate was 73% (30/41), 52% (12/23), 50% (3/6) and 0% (0/5) respectively. There was a significant improvement in implantation, clinical pregnancy and live birth rates for group I versus group IV (P = 0.0007, 0.0009, and 0.003, respectively) and for group II versus group IV (P = 0.009, 0.04 and 0.05, respectively). CONCLUSION: The use of a TNF-alpha inhibitor and IVIG significantly improves IVF outcome in young infertile women with Th1/Th2 cytokine elevation.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Fertilização in vitro , Imunoglobulinas Intravenosas/uso terapêutico , Fatores Imunológicos/uso terapêutico , Taxa de Gravidez , Adalimumab , Adulto , Anti-Inflamatórios/administração & dosagem , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Humanizados , Citocinas/sangue , Feminino , Citometria de Fluxo , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Fatores Imunológicos/administração & dosagem , Infertilidade Feminina/tratamento farmacológico , Gravidez
10.
Prenat Diagn ; 27(6): 566-7, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17385787

RESUMO

We describe a case of Harlequin Icthyosis where the main 2D and 3D ultrasound findings were digital contractures as opposed to the more commonly described severe facial dysmorphisms. A prenatal finding of distal arthrogryposis can therefore include harlequin icthyosis as a differential diagnosis, where 3D ultrasound may then disclose the facial features more commonly associated with the condition.


Assuntos
Artrogripose/diagnóstico por imagem , Ictiose Lamelar/diagnóstico por imagem , Ultrassonografia Pré-Natal/métodos , Acitretina/uso terapêutico , Adulto , Feminino , Humanos , Ictiose Lamelar/tratamento farmacológico , Recém-Nascido , Gravidez
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...